Natrol sales & earnings
This article was originally published in The Tan Sheet
Chatsworth, Calif.-based company will continue to invest in its recently launched Annasa network marketing subsidiary and expects to incur $1 mil.-$2 mil. in related expenses until the division reaches cash flow break even point in 2004, according to Natrol's 110-K report filed April 14 with the Securities & Exchange Commission. Firm recorded $6.1 mil. net loss in 2002, including a $6.8 mil. charge related to write off of goodwill from prior acquisitions. Sales fell 2.1% to $70.3 mil. for the year, due primarily to the firm's inability to increase its overall presence within "core mass-market and health food channels of trade" and intentional reduction of "slow moving and unprofitable items," Natrol says...
You may also be interested in...
Join us for an audio catch-up on the latest major developments in the global biopharma industry, as reported by
Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.
Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials.